The Food and Drug Administration (FDA) has granted Fast Track designation to CNTX-4975 (Centrexion) for the treatment of pain associated with knee osteoarthritis.
CNTX-4975 is a highly potent, ultrapure, synthetic form of trans-capsaicin. A Phase 2b trial, TRIUMPH, found that treatment with CNTX-4975 resulted in significant reductions in pain associated with knee osteoarthritis. Patients who received a single 1 mg injection of CNTX-4975 (n=71) had a decrease from baseline of –3.8 in Daily Pain with Walking (measured by AUC) compared to –1.3 for placebo (P =.0002).
“We look forward to building on the momentum of our CNTX-4975 program with the initiation of our Phase 3 program in patients with moderate to severe knee osteoarthritis in the first quarter of 2018,” said Randall M. Stevens, MD, CMO of Centrexion Therapeutics.
CNTX-4975 targets the capsaicin receptor (TRPV1), inactivating the local pain fibers transmitting signals to the brain; it is designed to be injected directly into the site of pain. Touch and pressure sensations are maintained but pain relief may last for months until the ends of the local pain fibers regenerate.
CNTX-4975 has also been granted Fast Track designation for Morton’s neuroma, a rare, painful foot condition.
Centrexion Therapeutics announces fast track designation granted by FDA to CNTX-4975 for treatment of osteoarthritis pain [press release]. Boston, MA; Centrexion Therapeutics Corporation: January 16, 2018. Accessed January 18, 2018.
This article originally appeared on MPR